


# IPSEN IN BRIEF: 2025

We are a global biopharmaceutical company with a focus on transformative medicines in our three therapeutic areas:



## Strategy

### Entire focus on specialty care

Opportunities for further growth across three therapeutic areas

### Global footprint

A well-balanced & expanded presence around the world

### Strong balance sheet & cash generation

Free cash flow  
>€750m <sup>1</sup> in 2024  
(+ 8.9%)



### Expanding pipeline

A good mix of new molecules and lifecycle management

### External-innovation strategy

Supported by a strong balance sheet and increased firepower

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovations and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit [ipsen.com](https://www.ipsen.com).

<sup>1</sup> Growth at constant exchange rates

# Ipsen Key Figures

**€3.4bn<sup>1</sup>**

Total sales  
(2024)

**31**

Approved products  
worldwide

**100+**

Countries where  
Ipsen medicines  
are marketed

**FY 2024 Total Sales Growth: +9.9%<sup>1</sup>**

## Oncology

Somatuline **1,121** | 5.6%  
Cabometyx **595** | 13.3%  
Decapeptyl **536** | -1.1%  
Onivyde **202** | 23.7%  
Tazverik **47** | 24.0%  
Other Oncology **4** | -11.2%


## Rare Disease

Bylvay **136**  
Iqirvo **22**  
Sohonos **21**

## Neuroscience


Dysport Ax **399** | 8.3%  
Dysport Tx **291** | 10.4%  
Other Neuroscience **11** | 12.0%

## Total Sales<sup>1</sup> (€M)



## Geographic Breakdown

Total sales by region: 2024



**North America**  
**34%**  
of total sales

**Europe**  
**39%**  
of total sales

**RoW**  
**27%**  
of total sales






In this map, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland.

<sup>1</sup> Growth at constant exchange rates

# External Innovation in 2024

## Early-stage

## Late-stage

 <p><b>Global licensing in oncology</b></p> <p>Preclinical antibody drug conjugate (ADC) target</p>	 <p><b>Strategic collaboration in neuroscience</b></p> <p>Up to two small molecules addressing RNA targets</p>	 <p><b>License &amp; R&amp;D collaboration in oncology</b></p> <p>Two preclinical precision T cell engagers from Marengo's Tri-STAR platform</p>	 <p><b>Global licensing in oncology</b></p> <p>Preclinical antibody-drug conjugate (ADC) with first-in-class potential</p>	 <p><b>Global licensing in immuno-oncology</b></p> <p>Preclinical novel T cell engager (TCE) with first-in-class potential</p>	 <p><b>Ex-U.S. licensing in pediatric oncology</b></p> <p>Regulatory submission of Tovorafenib in 2025</p>
--	---	---	--	---	---

# Focus of Generation Ipsen

## Environment

### GOALS<sup>1</sup>

Greenhouse gas emissions by 2030  
50% reduction in absolute Scope 1 & 2  
20% reduction in absolute Scope 3



100% of global electricity sourced from renewable energy by 2025

## Performance over 5 years

**45%**

% of reduction for  
Scopes 1 & 2<sup>1</sup>

**25%**

% of reduction for  
Scope 3<sup>1</sup>

**99.8%**

Renewable  
electricity across  
all sites

## People



Gender balance in  
Global Leadership  
Team

**55%**

of Women

## Rating

**S&P Global**

Ranked **61**

**MSCI**

Scored **A**



Scored **22.8**

## Khalid Deojee

Senior Manager, Investor Relations  
+33 6 66 01 95 26  
[khalid.deojee@ipssen.com](mailto:khalid.deojee@ipssen.com)

<sup>1</sup> Based on the 2019 baseline



[www.ipssen.com/investors](http://www.ipssen.com/investors)